The company attributed the growth of this business to its genetic screening, service, and environmental businesses.
PerkinElmer posted total third-quarter 2005 revenue of $361.9 million, a 6 percent increase over $341.6 million in the third quarter of 2004.
Earlier this month, the company said it planned to divest its Fluid Sciences business in order to focus on the health science market, which was responsible for 81 percent of PerkinElmer's total revenues for the quarter.
PerkinElmer reported net income of $31.8 million, a 32-percent increase over $24 million in the third quarter of 2004.
The company reported GAAP earnings per share from continuing operations of $.20, an increase of 43 percent over GAAP earnings per share of $.14 in the prior-year period.
PerkinElmer spent $21.8 million on R&D during the third quarter of 2005, up slightly from $20.4 million in the comparable period of 2004.
As of Oct. 2, PerkinElmer had cash and cash equivalents of $166.1 million.